Immuno-Oncology Advances in Applied Cellular Analysis - 14

Blocking "Don't Eat Me"
Signal on Cancer Cells
Lets Phagocytes Clean Up

Studies in mice have already shown that blocking
CD47 dramatically shrinks-and in some cases
completely eliminates-a wide range of human
solid tumor types. Such studies, for example, have
been conducted by a Stanford University Medical
Center-led team that has been characterizing, in
14

| GENengnews.com

ever greater detail, an intriguing phenomenon:
the expression of CD47 on the surface of tumor
cells can act as a "don't eat me" signal protecting
them from engulfment by phagocytic cells.
Back in 2012, the Stanford team showed that
using a tumor-targeting monoclonal antibody
to block CD47 on the surface of cancer cells
effectively removes this immunity to phagocytosis. The team's in vivo studies indicated that
when antibody therapy was started early after
engraftment of tumor cells in mice, the treated
animals were protected against tumor development, and remained tumor-free even after

ADDITIONAL CONTENT

Webinar
Real-Time Live-Cell Analysis
of Cellular Phagocytosis
Watch this webinar to learn how real-time live-cell analysis using
pH-sensitive fluorescent probe-labelled target cells can be used to
visualize and quantify phagocytosis. The session also covers data
on the pro-phagocytic effects of anti-CD47 antibodies.

Watch Now

Marcus Blanke/Getty Images

A

new therapeutic anticancer antibody is
being evaluated in clinical trials for human
solid malignancies and acute myelogenous
leukemia. The antibody, Hu5F9, targets the
human cell surface antigen CD47, with potential
immunostimulating and antineoplastic activities.

https://www.essenbioscience.com/en/resources/webinars/Real-time-analysis-cellular-phagocytosis/ http://www.GENengnews.com

Immuno-Oncology Advances in Applied Cellular Analysis

Table of Contents for the Digital Edition of Immuno-Oncology Advances in Applied Cellular Analysis